00:31 , May 15, 2019 |  BioCentury  |  Finance

Sofinnova Investments-led syndicate forms CV play CinCor with $50M, Roche castoff

Picking up one of Roche’s few remaining clinical cardiometabolism assets, Sofinnova Investments has joined Sofinnova Partners, 5AM Ventures and CinRx to launch CinCor with a $50 million series A and exclusive, worldwide rights to the...
21:14 , Oct 13, 2017 |  BC Week In Review  |  Clinical News

End of the road for Merck's anacetrapib

Merck & Co. Inc. (NYSE:MRK) said it will not seek regulatory approval of anacetrapib (MK-0859) to treat coronary heart disease (CHD). Anacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor. Although anacetrapib met the primary...
19:37 , Oct 12, 2017 |  BC Extra  |  Clinical News

End of the road for Merck's anacetrapib

Merck & Co. Inc. (NYSE:MRK) said it will not seek regulatory approval of anacetrapib (MK-0859) to treat coronary heart disease (CHD). Anacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor. Although anacetrapib met the primary...
21:57 , Jul 7, 2017 |  BioCentury  |  Product Development

One small CETP for Merck

Merck & Co. Inc. ’s massive cardiovascular outcomes trial for anacetrapib finally may have shown a CETP inhibitor provides a benefit. But the question remains whether the relative risk reduction is large enough for it...
22:33 , Jun 27, 2017 |  BC Extra  |  Clinical News

Merck's CETP inhibitor meets in CV outcomes study

Merck & Co. Inc. (NYSE:MRK) said cholesteryl ester transfer protein (CETP) inhibitor anacetrapib ( MK-0859 ) significantly reduced major coronary events in the Phase III REVEAL study, meeting its primary endpoint. Compared with placebo, anacetrapib...
07:00 , Apr 25, 2016 |  BioCentury  |  Finance

Saved by a SNP

At a time when venture dollars for cardiovascular companies are dwindling, DalCor Pharma U.K. Ltd. found a syndicate willing to go against the grain. Heart disease is still a leading cause of mortality, but many...
01:00 , Apr 20, 2016 |  BC Extra  |  Financial News

DalCor raises $100M in series B

DalCor Pharma U.K. Ltd. (London, U.K.) raised $100 million in a series B round with Sanderling Ventures, Andre Desmarais, Caisse de depot et placement du Quebec, the Fonds de solidarite FTQ, CTI Life Sciences and...
07:00 , Sep 21, 2015 |  BioCentury  |  Finance

Flower power

In three years, Forbion Capital Partners has turned a Japanese pharma's discarded cardiovascular asset into a return that could reach 50x. The key to the payday was the firm's conviction that prior failures of other...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Company News

Roche, DalCor deal

Roche granted DalCor exclusive, worldwide rights to develop and commercialize dalcetrapib. DalCor plans to start a Phase III trial in collaboration with the Montreal Heart Institute in 4Q15 for the small molecule inhibitor of cholesteryl...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Company News

Roche, DalCor deal

Roche will develop a companion diagnostic for DalCor’s dalcetrapib. The test will be used in a Phase III trial of the compound to target a specific genotype of patients who have experienced a recent acute...